Navigation Links
European patient survey add weight to expert call for greater clinical consensus on BTCP
Date:6/10/2010

Glasgow, UK 10 June, 2010 Further results from the European Survey of Breakthrough Cancer Pain1 were presented for the first time today at the 6th Research Congress of the European Association for Palliative Care (EAPC) in Glasgow.

The survey, which is the first international survey to look in detail at breakthrough cancer pain (BTCP) from a patient perspective, show that up to 45% of cancer patients experiencing breakthrough pain do not adhere to medication despite suffering from devastating episodes.

The low adherence to drug therapy is a remarkable discovery and demonstrates that current treatments arent adequately meeting patients needs during these incapacitating episodes of pain, explained Dr. Andrew Davies, Department of Palliative Medicine, Royal Marsden Hospital, UK and the principal investigator of this survey.

The survey, moreover, found that up to 50% of patients seek additional help from non-pharmacological methods such as heat, positional changes and rest demonstrating the need for improved pain relief. When asked about the ideal BTCP medication, patients wanted (in order of ranking)

  • A medication that relieves the pain completely
  • A medication that relieves the pain quickly
  • A medication that causes few side effects
  • A medication that is easy to use
  • A medication that can be given by a relative/carer

However, the results of the survey show that patients are not given a medication that matches these needs. 90% of patients were receiving oral opioids to manage their breakthrough pain. Studies have shown that the median interval from onset to peak intensity of the typical BTCP episode is only three minutes2 and that the average episode lasts between 30-60 minutes3, 4. The time to peak analgesic effect of oral opioids is documented to be approximately 60-90 minutes5, long after a majority of the episodes have ended.

Breakthrough pain is a distinct problem, and requires specific interventions including rescue medications that have an appropriately fast onset of action. Unfortunately, many patients are being treated with medications that are more suited to the management of persistent pain, and so are not receiving the most appropriate treatment for their breakthrough pain., said Dr. Andrew Davies.

A systematic literature review conducted with the purpose of assessing and classifying cancer breakthrough pain on behalf of the European Palliative Care Research Collaborative (EPCRC)6 likewise concludes that variations in cancer pain intensity are highly prevalent, yet the phenomenon is not well understood.

There is no widely accepted definition, classification system or well-validated assessment tool for cancer-related breakthrough pain, but there is strong concurrence on most of its key attributes. An internationally agreed upon definition and classification system for cancer-related breakthrough pain, and a standard approach on how to measure it is required in order to improve patient care and support research in this poor-prognosis cancer pain syndrome, said co-author, Professor Stein Kaasa, Chair of the European Association for Palliative Care Research Network (EAPC RN), principal investigator of the European Palliative Care Research Collaborative (EPCRC) and chair of the European Palliative Care Research Centre (PRC).


'/>"/>

Contact: Mette Thorn Srensen
mts@cohnwolfe.dk
45-41-38-43-00
Cohn & Wolfe
Source:Eurekalert

Related medicine news :

1. European Urology: Editorial about REDUCE trial underlines value of dutasteride
2. Third European Novel Food Approval Received by Tahitian Noni International
3. HCL Thames Medics says more locum doctors could help address European Working Time Directive shortage
4. European collaboration seeks to create World Wide Web for robots
5. European hematologist receives award to conduct research in US
6. The European Medicines Agency Completes Validation Stage for InterMunes Marketing Authorization Application for pirfenidone
7. Promega Maxwell 16 IVD System CE Marked to the European Union IVD Directive Delivers Combined Solution for Infectious Disease
8. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
9. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
10. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
11. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson ... offers insurance and financial preparation services, is providing an update on a charitable ... , Rock City Rescue is a locally recognized nonprofit that provides shelter and ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
Breaking Medicine Technology: